Loading patent…
AssigneeBASF Plant Science GmbH
InventorsMarkus Frank, Patrick Schweizer, Dimitar Douchkov
Estimating the term…
The invention relates to a method of generating or increasing a pathogen resistance in plants by reducing the expression of at least one stomatin polypeptide or a functional equivalent thereof. The invention relates to novel nucleic acid sequences coding for a Hordeum vulgare stomatin (HvSTM1) polynucleotide and describes homologous sequences (STM1) thereof, and to their use in methods for obtaining a pathogen resistance in plants, and to nucleic acid constructs, expression cassettes and vectors which comprise these sequences and which are suitable for mediating a fungal resistance in plants. The invention furthermore relates to transgenic organisms, in particular plants, which are transformed with these expression cassettes or vectors, and to cultures, parts or transgenic propagation material derived therefrom.
A method of increasing the resistance to pathogens in a plant or in a part of a plant, comprising altering the cell wall structure.
A method of increasing the resistance to pathogens in a plant or in a part of a plant, comprising reducing the activity of a stomatin STM1 protein in a plant or in a part of the plant.
A nucleic acid molecule coding for a stomatin STM1 protein, comprising at least one nucleic acid molecule selected from the group consisting of:
A nucleic acid construct comprising a nucleic acid molecule comprising at least one fragment of a nucleic acid molecule which is antisense or sense relative to a nucleic acid molecule coding for a stomatin STM1 polypeptide in operable linkage with a promoter selected from the group consisting of barley promoter, maize promoter, rice promoter, pathogen-inducible promoter, epidermis- and/or mesophyll-specific promoter and lemma-, palea- and/or glume (anther promodium)-specific promoter.
The transgenic nonhuman organism according toclaim 30, wherein the organism has an increased Bax inhibitor 1 protein, an ROR2 and/or SnAP34 activity and/or a reduced RacB, CSL1 and/or HvRBOHF activity.
Dependencies are inferred from the claim text.